Patent · US Active

Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

US9216200B2 · kind B2 · utility

3Cited by

180References

31Claims

0Family size

Assignee

Anthrogenesis Corporation · US

Inventors

Robert J. Hariri · New York, US
Mohammad Heidaran · Chatham, US
Lin Kang · Beijing, CN
Neerav D. PADLIYA · Scotch Plains, US
Ajai Pal · Bound Brook, US
Vanessa Voskinarian-Berse · Millington, US
Andrew Zeitlin · Green Brook, US
Xiaokui Zhang · Northborough, US

Key dates

Filing date	Aug 13, 2012
Grant date	Dec 22, 2015
Priority date	—
Expiry date	Aug 13, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2239/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.